Literature DB >> 106277

Prostatic carcinoma.

L A Klein.   

Abstract

Entities:  

Mesh:

Substances:

Year:  1979        PMID: 106277     DOI: 10.1056/NEJM197904123001504

Source DB:  PubMed          Journal:  N Engl J Med        ISSN: 0028-4793            Impact factor:   91.245


× No keyword cloud information.
  17 in total

1.  Urology-epitomes of progress: immediate versus delayed endocrine therapy for prostatic carcinoma.

Authors:  R Barnes; H Hadley; R T Bergman
Journal:  West J Med       Date:  1981-04

2.  The periodic health examination.

Authors:  L C Bartlett
Journal:  Can Med Assoc J       Date:  1981-02-15       Impact factor: 8.262

3.  Ultrasonography of the prostate: a preliminary report from Nigeria.

Authors:  B O Iko; J U Monu; E D Mangete; N R Nduka
Journal:  Int Urol Nephrol       Date:  1987       Impact factor: 2.370

4.  Early (stage A) prostatic cancer. VI. A critical look at the follow-up.

Authors:  S Battaglia; G Barbolini; A R Botticelli; G Berri; E Nigrisoli
Journal:  Virchows Arch A Pathol Anat Histol       Date:  1982

Review 5.  Epirubicin. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in cancer chemotherapy.

Authors:  G L Plosker; D Faulds
Journal:  Drugs       Date:  1993-05       Impact factor: 9.546

6.  Effect of oral clodronate on bone pain. A controlled study in patients with metastic prostatic cancer.

Authors:  I Elomaa; T Kylmälä; T Tammela; J Viitanen; J Ottelin; M Ruutu; K Jauhiainen; M Ala-Opas; L Roos; J Seppänen
Journal:  Int Urol Nephrol       Date:  1992       Impact factor: 2.370

7.  Glutathione depletion increases the cytotoxicity of melphalan to PC-3, an androgen-insensitive prostate cancer cell line.

Authors:  A Canada; L Herman; K Kidd; C Robertson; D Trump
Journal:  Cancer Chemother Pharmacol       Date:  1993       Impact factor: 3.333

8.  Phase II trial of 5-fluorouracil, high-dose leucovorin calcium, and dipyridamole in advanced prostate cancer.

Authors:  D Singh; J H Doroshow; L Leong; K Margolin; S Akman; J Raschko; G Somlo; R Morgan; J Harrison; J Cho
Journal:  J Cancer Res Clin Oncol       Date:  1992       Impact factor: 4.553

9.  Phase I/II dose-escalation study of liarozole in patients with stage D, hormone-refractory carcinoma of the prostate.

Authors:  E J Seidmon; D L Trump; W Kreis; S W Hall; M R Kurman; S P Ouyang; J Wu; A B Kremer
Journal:  Ann Surg Oncol       Date:  1995-11       Impact factor: 5.344

10.  Immunotherapy for Prostate Cancer with Gc Protein-Derived Macrophage-Activating Factor, GcMAF.

Authors:  Nobuto Yamamoto; Hirofumi Suyama; Nobuyuki Yamamoto
Journal:  Transl Oncol       Date:  2008-07       Impact factor: 4.243

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.